Markets Open July With M&A Jolt and Earnings In Focus
Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish
Deal of the Day
Vertex Pharmaceuticals grabbed the spotlight Monday. It agreed to buy Crinetics Pharmaceuticals for $85 per share in cash. CRNX stock doubled on the news. Short interest had sat at 13.6% of free float before the deal — shorts were caught badly offside. Options traders scrambled to reprice the move. It is one of the sharpest M&A jolts of the summer.
Earnings Week Ahead
Delta Air Lines headlines Thursday. Morgan Stanley raised its target to $115 on Monday. Short interest is just 3.5% of free float — bears are largely absent. Investors want clarity on summer travel demand and fuel costs. PepsiCo reports Wednesday, with Levi Strauss also posting Q2 results that day. Tariff risks remain a live concern for apparel names.
Bears and Short Squeezes
Hertz is the week's most extreme short story. Short interest hit 60.8% of free float. Borrow availability has hit zero — a textbook squeeze setup. CoreWeave also drew fresh bears, with SI jumping to 29.4%. An AI founder sold $7.1M in stock, adding fuel to the short thesis.
Europe: Defence Conviction
German defence group Rheinmetall saw its CEO buy over $8M in stock across two trades last week. The purchases signal strong personal confidence in the rally. PIMCO and Moody's both flagged risks in private credit today — warning that AI disruption could stress software-heavy loan books and slow Asia's credit growth.
Analyst Watch
HSBC cut targets on Regeneron and Zoetis sharply today, flagging healthcare pressure. UnitedHealth got the reverse treatment — its target lifted to $380 from $300 as the managed care giant attempts a recovery.
Stocks in this article
How this article was generated
- Generated
- 6 Jul 2026, 20:50
- Prompt version
- v1.0
- Data sources
- Short interestCost to borrowUtilizationOptions flowORTEX Alpha signalsORTEX Alpha signalsAnalyst consensus
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.